<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02976701</url>
  </required_header>
  <id_info>
    <org_study_id>DLBS1033-0716</org_study_id>
    <nct_id>NCT02976701</nct_id>
  </id_info>
  <brief_title>Effect of DLBS1033 After Primary PCI in Patients With STE-ACS</brief_title>
  <official_title>The Effect of DLBS1033 in Patients With ST Elevation Acute Coronary Syndrome (STE-ACS) After Primary Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dexa Medica Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Binawaluya Cardiac Hospital, Jakarta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dexa Medica Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, double-dummy, and controlled clinical study&#xD;
      over a total of 4-week therapy with DLBS1033 in the management of STE-ACS after a primary&#xD;
      PCI. There will be 40 STE-ACS subjects (20 subjects in each group) planned to complete the&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STE-ACS patients who undergo intermediate-delayed (&gt; 3 hours after the onset of the STEMI)&#xD;
      primary PCI will be enrolled in the study. Before the intervention, they will be given&#xD;
      standard medication for PCI.&#xD;
&#xD;
      Right after PCI, all eligible subjects will be assessed for microvascular perfusion, using a&#xD;
      pressure-temperature sensor-tipped coronary guidewire.&#xD;
&#xD;
      The day after, in addition to the dual antiplatelet therapy, i.e. 80 mg aspirin once daily&#xD;
      and clopidogrel 75 mg once daily, DLBS1033 at a dose of 980 mg three times daily or its&#xD;
      placebo will be given to the subjects for 4 weeks.&#xD;
&#xD;
      Clinical and laboratory examinations to evaluate the investigational drug's efficacy and&#xD;
      safety will be performed at Baseline (right after subjects undergo the primary PCI) and at&#xD;
      the End of study (week 4th of DLBS1033 therapy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of microvascular resistance (IMR)</measure>
    <time_frame>Week 4</time_frame>
    <description>Improvement in the index of microvascular resistance (IMR) from baseline to week 4th of treatment, measured using the pressure and temperature sensor-tipped guidewire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in fractional flow reserve (FFR) from baseline to week 4th of treatment, measured using the pressure and temperature sensor-tipped guidewire</measure>
    <time_frame>Week 4</time_frame>
    <description>Improvement in fractional flow reserve (FFR) from baseline and to Week 4th of treatment, measured using the pressure and temperature sensor-tipped guidewire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LV function</measure>
    <time_frame>Week 4</time_frame>
    <description>Improvement in several parameters of left ventricular (LV) function [EF, ESV, EDV], from baseline and to Week 4th of treatment will be measured by 2D echocardiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine hematology</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>Routine hematology, including: RBC, WBC, and platelet count, will be measured at baseline and week 4th of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine hematology (Hemoglobin)</measure>
    <time_frame>Week 0, 2 and 4</time_frame>
    <description>Hemoglobin will be measured at baseline and every interval of 2 weeks over the 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine hematology (Hematocrit)</measure>
    <time_frame>Week 0, 2 and 4</time_frame>
    <description>Hematocrit will be measured at baseline and every interval of 2 weeks over the 4 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>Liver function measured includes: serum ALT (SGPT), serum AST (SGOT), alkaline phosphatase, and total bilirubin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Week 0 and 4</time_frame>
    <description>Renal function measured includes: serum creatinine and BUN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemostasis parameter (Prothrombin time (PT))</measure>
    <time_frame>Week 0, 2, and 4</time_frame>
    <description>Prothrombin time (PT) will be measured at baseline and every interval of 2 weeks over the 4 weeks of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemostasis parameter (International Normalized Ratio (INR))</measure>
    <time_frame>Week 0, 2, and 4</time_frame>
    <description>International Normalized Ratio (INR) will be measured at baseline and every interval of 2 weeks over the 4 weeks of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Week 0 - 4</time_frame>
    <description>Adverse events (especially major and minor bleeding) are observed and carefully evaluated along the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>DLBS1033</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo is administered two tablets three times daily, everyday for four weeks of study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DLBS1033</intervention_name>
    <arm_group_label>DLBS1033</arm_group_label>
    <other_name>Disolf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy</intervention_name>
    <description>Standard therapy which consists of: aspirin enteric-coated tablet 1 x 80 mg and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.</description>
    <arm_group_label>DLBS1033</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Asp-Clopi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        KEY Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent.&#xD;
&#xD;
          2. Men or women of 30-75 years of age.&#xD;
&#xD;
          3. Evidence of acute ST elevation myocardial infarction (STEMI) at screening, as&#xD;
             confirmed by ECG presentation of STEMI: new ST elevation at the J point in two&#xD;
             contiguous leads with the cut-points: ≥ 0.1 mV in all leads other than leads V2-V3,&#xD;
             where the following cut-points apply: ≥ 0.2 mV in men ≥ 40 years, ≥ 0.25 mV in men &lt;&#xD;
             40 years, or ≥ 0.15 mV in women; or new or presumably new left bundle-branch block&#xD;
             (LBBB); and with at least one of the following:&#xD;
&#xD;
               -  Positive plasma biomarkers of myocardial necrosis (cardiac troponin I [cTnI]).&#xD;
&#xD;
               -  Possible ischaemic symptoms include various combinations of chest, upper&#xD;
                  extremity, mandibular or epigastric discomfort (with exertion or at rest) or an&#xD;
                  ischaemic equivalent such as dyspnoea or fatigue.&#xD;
&#xD;
          4. The onset of the STEMI is &gt; 3 hours before undergoing the primary PCI.&#xD;
&#xD;
          5. Therapy with study medication can be started within 24 hours after primary PCI.&#xD;
&#xD;
          6. Able to take oral medication.&#xD;
&#xD;
        KEY Exclusion Criteria:&#xD;
&#xD;
          1. Females of childbearing potential: pregnancy, breast-feeding.&#xD;
&#xD;
          2. History of hemorrhagic stroke, serious head injury within the last 3 months.&#xD;
&#xD;
          3. History of major surgery within the last 6 months.&#xD;
&#xD;
          4. History of PCI or CABG, or previous myocardial infarction.&#xD;
&#xD;
          5. Ongoing long term need for oral anticoagulants, antiplatelets, fibrinolytic, or&#xD;
             antithrombotic agents, other than the study medication.&#xD;
&#xD;
          6. Having any implanted pacemaker or cardiac resynchronization therapy (CRT) or cardiac&#xD;
             resynchronization therapy defibrillators (CRT-D).&#xD;
&#xD;
          7. Present with cardiogenic shock, 3rd degree atrioventricular (AV) block, complex&#xD;
             anatomical coronary condition.&#xD;
&#xD;
          8. Planned for a staged PCI within 30 days after the current PCI&#xD;
&#xD;
          9. Inadequate liver function&#xD;
&#xD;
         10. CRUSADE bleeding score of &gt; 30&#xD;
&#xD;
         11. Known or suspected allergy to other lumbrokinase products.&#xD;
&#xD;
         12. Prior experience with DLBS1033 or other oral lumbrokinase products.&#xD;
&#xD;
         13. Clinical evidence of malignancies with survival period &lt; 1 year.&#xD;
&#xD;
         14. Any other disease state, including chronic or acute systemic infections, uncontrolled&#xD;
             illnesses or other chronic diseases, which judged by the investigator, could&#xD;
             jeopardize patient's safety or interfere with trial participation or trial evaluation.&#xD;
&#xD;
         15. Subjects enrolled in other interventional protocol within 30 days prior to Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad Munawar, SpJP(K), MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Binawaluya Cardiac Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Muhammad Munawar, SpJP(K), MD</last_name>
    <phone>+62-21-87781605</phone>
    <email>muna@cbn.net.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jimmy Agung Pambudi, MD</last_name>
    <phone>+62-21-87781605</phone>
    <email>jimmyagung27@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Binawaluya Cardiac Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>13570</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Munawar, SpJP(K), MD</last_name>
      <phone>+62-21-87781605</phone>
      <email>muna@cbn.net.id</email>
    </contact>
    <contact_backup>
      <last_name>Jimmy Agung Pambudi, MD</last_name>
      <email>jimmyagung27@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Beny Hartono, SpJP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy A Pambudi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emile TH Parapat, SpJP, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STEMI</keyword>
  <keyword>acute coronary syndrome</keyword>
  <keyword>DLBS1033</keyword>
  <keyword>microvascular resistance index</keyword>
  <keyword>Left ventricular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

